Safety and feasibility of montelukast combined with budesonide in the treatment of children with asthma
10.3969/j.issn.1005-1678.2017.02.080
- VernacularTitle:孟鲁司特联合布地奈德治疗小儿哮喘的安全性与可行性
- Author:
Yongzhi YANG
;
Sujiao PAN
;
Lingyun SHEN
- Keywords:
montelukast;
budesonide;
asthma;
lung function;
inflammatory response
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(2):258-260,263
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the analysis of Montelukast joint Budesonide clinical curative effect and safety for the treatment of infantile asthma.Methods 80 cases of pediatric asthma patients from June 2014 to June 2016 in our hospital were selected as the research object, and randomly divided into observation group and the control group,40 cases in each group, the control group treated with conventional Budesonide therapy,the observation group with the Montelukast with Budesonide therapy, compared to observe the clinical therapeutic effects of two groups of children and its adverse reactions.Results Observation group with clinical total effective rate was 100.00%, which was significantly higher than the control group 82.50%(P<0.05);The time of disappearance of asthma, the disappearance time of cough, wheezing and the disappearance of wet sound were shorter in observation group than in control group (P<0.05); After treatment,After treatment, the observation group PEF, FEV1, FEVI /FVC scores were significantly better than the control group, and observation group Hs-CRP, TNF-α, IL-6, IL-10 indicators improved better than the control group, With statistical significance (P<0.05); But there was no significant difference between the two groups in adverse reaction rate.Conclusion Children with asthma by Montelukast with Budesonide therapy of clinical effect is remarkable, can effectively improve the clinical symptoms, and will not increase adverse reactions, has high clinical application security.
